Compare ARW & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | RYTM |
|---|---|---|
| Founded | 1935 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 1994 | 2017 |
| Metric | ARW | RYTM |
|---|---|---|
| Price | $168.89 | $86.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $136.00 | $131.14 |
| AVG Volume (30 Days) | 461.3K | ★ 921.3K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.93 | 28.34 |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $30,852,935,000.00 | N/A |
| Revenue This Year | $13.19 | $54.90 |
| Revenue Next Year | $4.51 | $86.58 |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | ★ 10.49 | N/A |
| 52 Week Low | $100.26 | $55.31 |
| 52 Week High | $179.28 | $122.20 |
| Indicator | ARW | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 49.31 |
| Support Level | $109.60 | $84.39 |
| Resistance Level | N/A | $93.51 |
| Average True Range (ATR) | 5.38 | 4.22 |
| MACD | 3.14 | 0.86 |
| Stochastic Oscillator | 77.49 | 77.88 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the global components business and the global enterprise computing solutions.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.